个人简介
1980 – 1984武汉大学,化学学士; 1984-1987武汉大学,物理化学硕士; 1987-1990中科院生物物理研究所,生物化学博士; 1990-1993美国德克萨斯大学西南医学中心从事博士后研究工作; 1994-2005美国礼来制药公司,高级科学家和药物新药开发部主管; 2005-2008美国印地安纳大学化学和生物化学系任副教授; 2008-2010中美冠科生物医药有限公司总裁; 2012 - 至今 武汉大学药学院教授。
研究领域
1.降糖生物多肽的结构改造,多肽激动剂与受体的相互作用及信号传导,多肽药物的给药途径。 2.高特异性抗VEGF单克隆抗体的人源化及药理学研究。 3. 新型Check-Point 靶向抗癌及抗病毒药物的生物化学及药理学研究。
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
1. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE . Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15180-8. 2. Rogers T, Li P, Smiley D, DiMarchi RD, and Zhang F., (2007), Design, synthesize and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601. 3. Singh J, Ling L, Sawyer JS, Lee W, Zhang F, Yingling JM., (2005), Successful discovery of TbRI (ALK5) kinase inhibitors using HTS, target-hopping and virtual screening, Chemistry Today, 23 (3): 35-38. 4. Hamdouchi C, Zhong B, Mendoza J, Zhang F et al. (2005), Structure-Based Design of a New Class of Highly Selective Aminoimidazo[1,2-á]pyridine-Based Inhibitors of Cyclin Dependent Kinases,bioorganic & Medicinal Chemistry Letters. 15 (7): 1943-1947. 5. Jaramillo C, Zhang F. et al (2004), Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation, bioorganic & Medicinal Chemistry Letters. 14(24): 6095-6099. 6. J. Singh, J. Yingling, Zhang F, et al (2004), Transforming the TGF-â pathway: Convergence of distinct lead generation strategies on a novel kinase pharmcophroe for TbRI, Current Opinion in Drug Discovery and Development 7(4): 10-20. 7. Al-Awar RS, Ray JE, Zhang F. etal (2004). Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg Med Chem Lett. 14(15): 3925-3928. 8. Sawyer JS, Beight DW, Zhang F, Yingling JM (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett. 14(13): 3581-3584. 9. Hadouchi C, Keyser H, Zhang F, Brooks H, et al (2004). The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a]pyridines. Molecular Cancer Therapeutics. 3(1):1-9 10. Vincent J.-P, Johnson RB, Parsons S, Zhang F, Wang QM (2003). Identification of a C-terminal regulatory motif in hepatitis C virus RNA-dependent RNA polymerase: structural and biochemical analysis. J. Virology. 77: 9020-9028 11. Sanchez-Martinez C, Shih C, Zhu G, Dempsey JA, Zhang F (2003) . Studies on Cyclin Dependent Kinase Inhibitors:Indolo[2,3-a]pyrrolo[3,4-c]carbazoles versus Bis-indolylmaleimides, Bioorganic & Medicinal Chemistry Letters 13:3841-3846. 12. Vieth M, Brooks H, Hamdouchi C, McMillen W, Sawyer JS, Yingling J, and Zhang F(2003). Combining Medicinal Chemistry with Chemogenomic and Computer-Aided Structure-Based Design in Development of Novel Kinase Inhibitors, Cell. Mol. Biol. Lett 8 (2A):566-567 13. Sawyer JS, Herron DK, Edward CR, Zhang F, and Yingling J (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-beta Type I Receptor Kinase Domain. Journal of Medicinal Chemistry 46 (19):3953-3956. 14. Wang QM, Hockman M, Staschke K, Zhang F, Parsons S (2002). Oligomerization and Cooperative RNA Synthesis Activity of HCV RNA-Dependent RNA Polymerase, J. Virology. 76:3865-3872 15. Jin L, Briggs S, Clawson D, Schevitz R, Smiley D, Tashjian A, Zhang F (2000). “Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9 Å Resolution”, J. Biol. Chem. 275:27238-27244. 16. Zhang F, Basinski M, DiMarchi RD et al. (1997) “Crystal Structure of the Obese Protein Leptin-E100”, Nature 387:206-209 17. Zhang J, Zhang F, Ebert D, Cobb MH, and Goldsmith EJ(1995) “Activity of the MAP Kinase ERK2 is Controlled by a Flexible Surface Loop”, Structure 3:299-307. 18. Zhang F, Strand A, Robbins D, Cobb MH, and Goldsmith EJ (1994) “Crystal Structure of MAP kinase ERK2 at 2.3Å Resolution”. Nature. 367: 704-711.